Indomethacin SR
Phase 3Small molecule
Indomethacin SR is one of 25 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Acute Pancreatitis
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Merrem
BB. Braun Medical Inc.
Approved
VIOKACE
AbbVieApproved
Relistor
SSalix
Approved
Advil
KKenvue Brands
Approved
Zocor
OOrganon and Co
Approved
Symproic
BBioDelivery Sciences International
Phase 3
Esbriet
LLegacy Health System
Phase 2
Indomethacin SR
PPeking Union Medical College Hospital
Phase 3
Bayer Aspirin
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Pancreatitis1 trial
Arthritis1 trial
Apremilast Therapy for Acute Gouty Arthritis
Withdrawn·—·Phase 2·NCT00997581
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Indomethacin SR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details